Search Medical Condition
Please enter condition
Please choose location
Clear Trial Filters

Chronic Obstructive Lung Disease Clinical Trials

A listing of Chronic Obstructive Lung Disease medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.


Found (26) clinical trials

Ultibro Versus Spiriva Alone to Reduce Exertional Dyspnea in Patients With Moderate to Severe COPD

The foundation of COPD therapy is to combine inhaled therapy to optimize benefits as it was done several years ago by associating short-acting 2-agonists and muscarinic antagonist. The recent availability of once-daily LABA/LAMA fixed combination products makes this therapeutic strategy even more appealing and appears as a promising treatment option ...


A clinical research study of Danirixin 35 mg tablets, Placebo, Rescue medication

This is a pilot study to investigate the effect of danirixin hydrobromide 35 milligram (mg) tablets on lung function and health related quality of life (HRQoL) in subjects with mild to moderate airflow obstruction and a demonstrated history of decline in forced expiratory volume in one second (FEV1). Specifically, this ...


Patients are needed to participate in a clinical research study of Chronic Obstructive Lung Disease to evaluate Nemiralisib ELLIPTA 250 µg, Nemiralisib ELLIPTA 50 µg, Standard of care therapy, Albuterol (Salbutamol) MDI or nebules, Nemiralisib ELLIPTA 500 µg, Placebo ELLIPTA, Nemiralisib ELLIPTA 100 µg, Nemiralisib ELLIPTA 750 µg

Nemiralisib is being developed as an anti-inflammatory drug for the treatment of inflammatory airways disease. This study is designed to assess the dose response, efficacy, safety, and pharmacokinetics of nemiralisib across a range of doses [up to 750 micrograms (g)] compared with placebo. The study consists of a Screening Period, ...


Study to Patients With Stable COPD to Assess the Efficacy and Safety of Aclidinium Bromide/Formoterol Fumarate (DUAKLIR)

This is a multiple dose, randomised, parallel, double blind, double dummy, multicentre and multinational Phase III study to determine the efficacy and safety of Aclidinium bromide/Formoterol fumarate compared with individual components and placebo and Aclidinium bromide compared with Placebo when administered to patients with stable Chronic Obstructive Pulmonary Disease (COPD).


Danirixin Dose Ranging Study in Participants With Chronic Obstructive Pulmonary Disease (COPD)

Danirixin (DNX) is a selective CXC chemokine receptor (CXCR2) antagonist being developed as a potential anti-inflammatory agent for the treatment of COPD. This is a Phase 2, randomized, double-blind (Sponsor Open) study. The primary objective of the study is to evaluate the clinical activity and safety of danirixin compared with ...


An Observational Outcomes Study for Autologous Cell Therapy Among Patients With COPD and Interstitial Lung Disease

Through the collection of outcome data, Lung Institute aims to explore and describe the safety and efficacy of autologous stem cell treatment for chronic lung disease with dissemination to the public and to the medical community for the advancement of regenerative medicine. The study aims to confirm the safety of ...

Phase N/A

Comparative Study of Error Rates Between ELLIPTA Dry Powder Inhaler (DPI) and Other DPIs

For effective drug delivery using inhalation route, it is important to use the inhalers correctly. This open-label study will evaluate the error rates during the use of ELLIPTA DPI, alone or in combination, in comparison with other DPIs. The study aims to provide clinical evidence in subjects with COPD that ...

Phase N/A

Occurrence of Potential Bacterial and Viral Pathogens in Stable Chronic Obstructive Pulmonary Disease and During Acute Exacerbations of the Disease in Asia Pacific

The protocol has been amended to implement the following changes: Alignment of the protocol to the updated GOLD consensus report of 2017 and the COPD fact sheet. Alignment of the study endpoints to the study objectives.

Phase N/A